Karol Axcrona
Position: MD, PhD
Phone: +47 22 93 40 00
Email:

Publications by Karol Axcrona

47 publications found

Publications 2017

  1. Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
    Correction: MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
    Oncotarget, 8 (4), 7208-7213
    PubMed 28179591
  2. Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2017)
    Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study
    Prostate, 77 (8), 859-865
    PubMed 28240424
  3. Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD (2017)
    Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway
    Urology, 110, 140-147
    PubMed 28823634

Publications 2016

  1. Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2016)
    MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
    Oncotarget, 7 (26), 40297-40313
    PubMed 27248169
  2. Lilleaasen G, Davami J, Axcrona K, Müller S (2016)
    ERAS for radical cystectomy-first year results after implementation of ERAS using the EIAS database
    Clin Nutr ESPEN, 12, e42
    PubMed 28531704
  3. Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
    Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
    Clin Nutr, 36 (3), 672-679
    PubMed 27406859
  4. Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2016)
    Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality
    Prostate, 76 (12), 1088-94
    PubMed 27271973
  5. Østby-Deglum M, Axcrona K, Brennhovd B, Dahl AA (2016)
    Ability to Reach Orgasm in Patients With Prostate Cancer Treated With Robot-assisted Laparoscopic Prostatectomy
    Urology, 92, 38-43
    PubMed 26972145

Publications 2015

  1. Saeter T, Bogaard M, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
    The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort
    Prostate, 76 (2), 207-14
    PubMed 26477789
  2. Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
    The prognostic value of reactive stroma on prostate needle biopsy: a population-based study
    Prostate, 75 (6), 662-71
    PubMed 25620661
  3. Østby-Deglum M, Brennhovd B, Axcrona K, Fosså SD, Dahl AA (2015)
    A comparative study of erectile function and use of erectile aids in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy
    Scand J Urol, 49 (6), 433-439
    PubMed 26116048

Publications 2014

  1. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A et al. (2014)
    Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
    Eur Urol, 66 (3), 489-99
    PubMed 24484606
  2. Jakobsen JK, Krarup KP, Kirrander P, Håkansson U, Kaipia A, Perttila I, Axcrona K, Torkelsen TK, Hilmarsson R, Jensen JB, Scandinavian Penile Cancer Group (SCAPECA) (2014)
    Penile cancer in Scandinavia: Current practice and future perspectives
    Scand J Urol, 50 (1), 90-2
    PubMed 25438987
  3. Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H (2014)
    The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
    Br J Cancer, 112 (2), 382-90
    PubMed 25461803
  4. Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K (2014)
    Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience
    Scand J Urol, 49 (3), 218-23
    PubMed 25428750
  5. Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K (2014)
    The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy
    Urol Int, 93 (3), 289-95
    PubMed 25170745

Publications 2013

  1. Brennhovd B, Axcrona K, Fosså SD, Giercksky KE, Vlatkovic L, Dahl AA (2013)
    Robot-assisted radical prostatectomy of clinical high-risk patients with prostate cancer: a controlled study of operative and short-term postoperative events
    Scand J Urol, 47 (6), 449-55
    PubMed 24328733
  2. Liu Y, Sæter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, Giercksky KE, Nesland JM, Suo ZH, Axcrona K (2013)
    Dendritic and lymphocytic cell infiltration in prostate carcinoma
    Histol Histopathol, 28 (12), 1621-8
    PubMed 23729368
  3. Liu Y, Wu X, Li X, Kvalheim G, Axcrona U, Axcrona K, Suo Z (2013)
    Blocking mtDNA replication upregulates the expression of stemness-related genes in prostate cancer cell lines
    Ultrastruct Pathol, 37 (4), 258-66
    PubMed 23634795
  4. Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z (2013)
    SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas
    PLoS One, 8 (7), e70558
    PubMed 23936228

Publications 2012

  1. Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P (2012)
    Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide
    BJU Int, 110 (11), 1721-8
    PubMed 22500884
  2. Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, Knutstad K, Olsen DR, Seierstad T (2012)
    Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance
    Eur Radiol, 23 (4), 1158-66
    PubMed 23114883
  3. Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, Giercksky KE, Axcrona K (2012)
    Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
    Int J Urol, 19 (8), 749-56
    PubMed 22487487
  4. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, Nesland JM, Suo Z (2012)
    Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines
    Tumour Biol, 33 (4), 967-78
    PubMed 22252524
  5. Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE (2012)
    Androgen deprivation therapy: past, present and future
    BJU Int, 109 Suppl 6, 1-12
    PubMed 22672120
  6. Steinsvik EA, Axcrona K, Angelsen A, Beisland C, Dahl A, Eri LM, Haug ES, Svindland A, Fosså S (2012)
    Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? Findings from a prospective national study
    Scand J Urol, 47 (2), 92-100
    PubMed 22860630
  7. Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S (2012)
    Bother problems in prostate cancer patients after curative treatment
    Urol Oncol, 31 (7), 1067-78
    PubMed 22341412

Publications 2011

  1. Axcrona K, Vlatkovic L, Hovland J, Brennhovd B, Kongsgaard U, Giercksky KE (2011)
    Robot-assisted laparoscopic prostatectomy in a 68-year-old patient with previous heart transplantation and pelvic irradiation
    J Robot Surg, 6 (1), 81-3
    PubMed 22408687
  2. Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K (2011)
    Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies
    BJU Int, 110 (2 Pt 2), E69-75
    PubMed 22093091
  3. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM, Suo Z (2011)
    Prostate cancer cell lines under hypoxia exhibit greater stem-like properties
    PLoS One, 6 (12), e29170
    PubMed 22216200
  4. Servoll E, Saeter T, Vlatkovic L, Lund T, Nesland J, Waaler G, Axcrona K, Beisland HO (2011)
    Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer
    BJU Int, 109 (10), 1489-94
    PubMed 21933333
  5. Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fosså SD (2011)
    Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother
    BJU Int, 109 (9), 1366-74
    PubMed 21999333
  6. Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S (2011)
    Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones
    Prostate, 72 (6), 668-76
    PubMed 21809351

Publications 2010

  1. Axcrona K, Brennhovd B, Andersen M, Berner A (2010)
    Sarcomatoid squamous cell carcinoma of the penis
    Acta Oncol, 49 (1), 128-30
    PubMed 20100148
  2. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A et al. (2010)
    Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
    BJU Int, 107 (1), 28-39
    PubMed 20840664
  3. Steinsvik EA, Fosså SD, Axcrona K, Fransson P, Widmark A, Dahl AA (2010)
    Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer
    J Urol, 184 (2), 525-31
    PubMed 20620412
  4. Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S (2010)
    Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center
    Acta Oncol, 50 (3), 408-14
    PubMed 20586661

Publications 2009

  1. Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
    [Incorrect about hormone treatment in prostatic cancer]
    Tidsskr Nor Laegeforen, 129 (5), 429
    PubMed 19247406
  2. Hernes E, Kyrdalen A, Kvåle R, Hem E, Klepp O, Axcrona K, Fosså SD (2009)
    Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry
    BJU Int, 105 (6), 805-11; discussion 811
    PubMed 19735258

Publications 2007

  1. Axcrona K, Brennhovd B, Alfsen GC, Giercksky KE, Warloe T (2007)
    Photodynamic therapy with methyl aminolevulinate for atypial carcinoma in situ of the penis
    Scand J Urol Nephrol, 41 (6), 507-10
    PubMed 17853049
  2. Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
    Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
    Acta Oncol, 46 (8), 1195-7
    PubMed 17851841

Publications 2006

  1. Brennhovd B, Johnsrud K, Berner A, Bogsrud T, Waehre H, Giercksky KE, Axcrona K (2006)
    Sentinel node procedure in low-stage/low-grade penile carcinomas
    Scand J Urol Nephrol, 40 (3), 204-7
    PubMed 16809260

Publications 2002

  1. Frick IM, Axcrona K, Härdig Y, Tapper H, Gustafsson L, Kellner R, Leanderson T, Björck L (2002)
    Uptake and intracellular transportation of a bacterial surface protein in lymphoid cells
    Mol Microbiol, 44 (4), 917-34
    PubMed 12010489

Publications 2001

  1. Lindgren H, Axcrona K, Leanderson T (2001)
    Regulation of transcriptional activity of the murine CD40 ligand promoter in response to signals through TCR and the costimulatory molecules CD28 and CD2
    J Immunol, 166 (7), 4578-85
    PubMed 11254715

Publications 1998

  1. Axcrona K, Akerblad P, Leanderson T (1998)
    Phenotypic convergence and divergence of surface immunoglobulin and CD40 signals
    Scand J Immunol, 47 (3), 210-7
    PubMed 9519858

Publications 1996

  1. Axcrona K, Gray D, Leanderson T (1996)
    Regulation of B cell growth and differentiation via CD21 and CD40
    Eur J Immunol, 26 (9), 2203-7
    PubMed 8814268

Publications 1995

  1. Axcrona K, Björck L, Leanderson T (1995)
    Multiple ligand interactions for bacterial immunoglobulin-binding proteins on human and murine cells of the hematopoetic lineage
    Scand J Immunol, 42 (3), 359-67
    PubMed 7660068
 

Author network for Karol Axcrona by COREMINE medical


Publications 2017

Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
Correction: MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
Oncotarget, 8 (4), 7208-7213
PubMed 28179591

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2017)
Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study
Prostate, 77 (8), 859-865
PubMed 28240424

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD (2017)
Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway
Urology, 110, 140-147
PubMed 28823634

Publications 2016

Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2016)
MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
Oncotarget, 7 (26), 40297-40313
PubMed 27248169

Lilleaasen G, Davami J, Axcrona K, Müller S (2016)
ERAS for radical cystectomy-first year results after implementation of ERAS using the EIAS database
Clin Nutr ESPEN, 12, e42
PubMed 28531704

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
PubMed 27406859

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2016)
Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality
Prostate, 76 (12), 1088-94
PubMed 27271973

Østby-Deglum M, Axcrona K, Brennhovd B, Dahl AA (2016)
Ability to Reach Orgasm in Patients With Prostate Cancer Treated With Robot-assisted Laparoscopic Prostatectomy
Urology, 92, 38-43
PubMed 26972145

Publications 2015

Saeter T, Bogaard M, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort
Prostate, 76 (2), 207-14
PubMed 26477789

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The prognostic value of reactive stroma on prostate needle biopsy: a population-based study
Prostate, 75 (6), 662-71
PubMed 25620661

Østby-Deglum M, Brennhovd B, Axcrona K, Fosså SD, Dahl AA (2015)
A comparative study of erectile function and use of erectile aids in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy
Scand J Urol, 49 (6), 433-439
PubMed 26116048

Publications 2014

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A et al. (2014)
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
Eur Urol, 66 (3), 489-99
PubMed 24484606

Jakobsen JK, Krarup KP, Kirrander P, Håkansson U, Kaipia A, Perttila I, Axcrona K, Torkelsen TK, Hilmarsson R, Jensen JB, Scandinavian Penile Cancer Group (SCAPECA) (2014)
Penile cancer in Scandinavia: Current practice and future perspectives
Scand J Urol, 50 (1), 90-2
PubMed 25438987

Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H (2014)
The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
Br J Cancer, 112 (2), 382-90
PubMed 25461803

Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K (2014)
Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience
Scand J Urol, 49 (3), 218-23
PubMed 25428750

Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K (2014)
The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy
Urol Int, 93 (3), 289-95
PubMed 25170745

Publications 2013

Brennhovd B, Axcrona K, Fosså SD, Giercksky KE, Vlatkovic L, Dahl AA (2013)
Robot-assisted radical prostatectomy of clinical high-risk patients with prostate cancer: a controlled study of operative and short-term postoperative events
Scand J Urol, 47 (6), 449-55
PubMed 24328733

Liu Y, Sæter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, Giercksky KE, Nesland JM, Suo ZH, Axcrona K (2013)
Dendritic and lymphocytic cell infiltration in prostate carcinoma
Histol Histopathol, 28 (12), 1621-8
PubMed 23729368

Liu Y, Wu X, Li X, Kvalheim G, Axcrona U, Axcrona K, Suo Z (2013)
Blocking mtDNA replication upregulates the expression of stemness-related genes in prostate cancer cell lines
Ultrastruct Pathol, 37 (4), 258-66
PubMed 23634795

Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z (2013)
SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas
PLoS One, 8 (7), e70558
PubMed 23936228

Publications 2012

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P (2012)
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide
BJU Int, 110 (11), 1721-8
PubMed 22500884

Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, Knutstad K, Olsen DR, Seierstad T (2012)
Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance
Eur Radiol, 23 (4), 1158-66
PubMed 23114883

Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, Giercksky KE, Axcrona K (2012)
Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Int J Urol, 19 (8), 749-56
PubMed 22487487

Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, Nesland JM, Suo Z (2012)
Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines
Tumour Biol, 33 (4), 967-78
PubMed 22252524

Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE (2012)
Androgen deprivation therapy: past, present and future
BJU Int, 109 Suppl 6, 1-12
PubMed 22672120

Steinsvik EA, Axcrona K, Angelsen A, Beisland C, Dahl A, Eri LM, Haug ES, Svindland A, Fosså S (2012)
Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? Findings from a prospective national study
Scand J Urol, 47 (2), 92-100
PubMed 22860630

Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S (2012)
Bother problems in prostate cancer patients after curative treatment
Urol Oncol, 31 (7), 1067-78
PubMed 22341412

Publications 2011

Axcrona K, Vlatkovic L, Hovland J, Brennhovd B, Kongsgaard U, Giercksky KE (2011)
Robot-assisted laparoscopic prostatectomy in a 68-year-old patient with previous heart transplantation and pelvic irradiation
J Robot Surg, 6 (1), 81-3
PubMed 22408687

Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K (2011)
Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies
BJU Int, 110 (2 Pt 2), E69-75
PubMed 22093091

Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM, Suo Z (2011)
Prostate cancer cell lines under hypoxia exhibit greater stem-like properties
PLoS One, 6 (12), e29170
PubMed 22216200

Servoll E, Saeter T, Vlatkovic L, Lund T, Nesland J, Waaler G, Axcrona K, Beisland HO (2011)
Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer
BJU Int, 109 (10), 1489-94
PubMed 21933333

Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fosså SD (2011)
Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother
BJU Int, 109 (9), 1366-74
PubMed 21999333

Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S (2011)
Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones
Prostate, 72 (6), 668-76
PubMed 21809351

Publications 2010

Axcrona K, Brennhovd B, Andersen M, Berner A (2010)
Sarcomatoid squamous cell carcinoma of the penis
Acta Oncol, 49 (1), 128-30
PubMed 20100148

Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A et al. (2010)
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
BJU Int, 107 (1), 28-39
PubMed 20840664

Steinsvik EA, Fosså SD, Axcrona K, Fransson P, Widmark A, Dahl AA (2010)
Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer
J Urol, 184 (2), 525-31
PubMed 20620412

Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S (2010)
Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center
Acta Oncol, 50 (3), 408-14
PubMed 20586661

Publications 2009

Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
[Incorrect about hormone treatment in prostatic cancer]
Tidsskr Nor Laegeforen, 129 (5), 429
PubMed 19247406

Hernes E, Kyrdalen A, Kvåle R, Hem E, Klepp O, Axcrona K, Fosså SD (2009)
Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry
BJU Int, 105 (6), 805-11; discussion 811
PubMed 19735258

Publications 2007

Axcrona K, Brennhovd B, Alfsen GC, Giercksky KE, Warloe T (2007)
Photodynamic therapy with methyl aminolevulinate for atypial carcinoma in situ of the penis
Scand J Urol Nephrol, 41 (6), 507-10
PubMed 17853049

Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
Acta Oncol, 46 (8), 1195-7
PubMed 17851841

Publications 2006

Brennhovd B, Johnsrud K, Berner A, Bogsrud T, Waehre H, Giercksky KE, Axcrona K (2006)
Sentinel node procedure in low-stage/low-grade penile carcinomas
Scand J Urol Nephrol, 40 (3), 204-7
PubMed 16809260

Publications 2002

Frick IM, Axcrona K, Härdig Y, Tapper H, Gustafsson L, Kellner R, Leanderson T, Björck L (2002)
Uptake and intracellular transportation of a bacterial surface protein in lymphoid cells
Mol Microbiol, 44 (4), 917-34
PubMed 12010489

Publications 2001

Lindgren H, Axcrona K, Leanderson T (2001)
Regulation of transcriptional activity of the murine CD40 ligand promoter in response to signals through TCR and the costimulatory molecules CD28 and CD2
J Immunol, 166 (7), 4578-85
PubMed 11254715

Publications 1998

Axcrona K, Akerblad P, Leanderson T (1998)
Phenotypic convergence and divergence of surface immunoglobulin and CD40 signals
Scand J Immunol, 47 (3), 210-7
PubMed 9519858

Publications 1996

Axcrona K, Gray D, Leanderson T (1996)
Regulation of B cell growth and differentiation via CD21 and CD40
Eur J Immunol, 26 (9), 2203-7
PubMed 8814268

Publications 1995

Axcrona K, Björck L, Leanderson T (1995)
Multiple ligand interactions for bacterial immunoglobulin-binding proteins on human and murine cells of the hematopoetic lineage
Scand J Immunol, 42 (3), 359-67
PubMed 7660068